Abivax secures EUR15m non-dilutive financing from Kreos Capital
Abivax, a clinical-stage biotechnology company harnessing the immune system to develop treatments for inflammatory diseases, viral diseases and cancer, has obtained a EUR15 million non-dilutive debt financing from Kreos Capital, with an additional EUR5 million to be decided before 2020 year-end.This financing comprises two tranches of EUR10 million and EUR5
